- Home
- LYEL vs ACRE Comparison
LYEL vs ACRE Comparison
Compare LYEL & ACRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- ACRE
- Stock Information
- Founded
- LYEL 2018
- ACRE 2011
- Country
- LYEL United States
- ACRE United States
- Employees
- LYEL N/A
- ACRE N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- ACRE Real Estate Investment Trusts
- Sector
- LYEL Health Care
- ACRE Real Estate
- Exchange
- LYEL Nasdaq
- ACRE Nasdaq
- Market Cap
- LYEL 207.7M
- ACRE 244.2M
- IPO Year
- LYEL 2021
- ACRE 2012
- Fundamental
- Price
- LYEL $12.82
- ACRE $4.84
- Analyst Decision
- LYEL Sell
- ACRE Hold
- Analyst Count
- LYEL 2
- ACRE 6
- Target Price
- LYEL $15.00
- ACRE $5.31
- AVG Volume (30 Days)
- LYEL 24.3K
- ACRE 422.7K
- Earning Date
- LYEL 11-06-2025
- ACRE 11-06-2025
- Dividend Yield
- LYEL N/A
- ACRE 12.35%
- EPS Growth
- LYEL N/A
- ACRE N/A
- EPS
- LYEL N/A
- ACRE N/A
- Revenue
- LYEL $60,000.00
- ACRE $80,674,000.00
- Revenue This Year
- LYEL N/A
- ACRE N/A
- Revenue Next Year
- LYEL N/A
- ACRE N/A
- P/E Ratio
- LYEL N/A
- ACRE N/A
- Revenue Growth
- LYEL 11.11
- ACRE 58.54
- 52 Week Low
- LYEL $7.65
- ACRE $3.35
- 52 Week High
- LYEL $32.00
- ACRE $7.83
- Technical
- Relative Strength Index (RSI)
- LYEL 64.71
- ACRE 55.55
- Support Level
- LYEL $12.59
- ACRE $4.62
- Resistance Level
- LYEL $13.50
- ACRE $4.95
- Average True Range (ATR)
- LYEL 0.67
- ACRE 0.14
- MACD
- LYEL 0.18
- ACRE 0.01
- Stochastic Oscillator
- LYEL 76.87
- ACRE 52.38
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.